Reimbursed Care Access in Dominican Republic

Currently classified as a controlled substance under the Dominican Republic’s Law No. 50-88 on drugs and controlled substances and its implementing regulation (Decreto No. 288-96); there is no established national reimbursement pathway or public insurance coverage for psilocybin-based treatments and no publicly available regulatory approval for therapeutic psilocybin products outside of approved clinical research. # #

Currently classified as a controlled substance under Law No. 50-88 and the related regulatory framework; there is no routine medical or reimbursed access to MDMA-assisted psychotherapy in the Dominican Republic, and any access would be limited to formally authorised clinical research under national law and oversight by competent authorities. Currently no public reimbursement pathway exists for MDMA therapies. # #

Ketamine (racemate) is an established medicinal anaesthetic in health systems worldwide and appears on the WHO Model List of Essential Medicines for injectable anaesthesia; in the Dominican Republic ketamine as an anaesthetic is administered in medical settings consistent with national drug-control and pharmaceutical regulation, but there is no publicly documented, nationwide reimbursement program specific to esketamine (the esketamine nasal product marketed in some jurisdictions for treatment‑resistant depression) and no evidence of an established, reimbursed esketamine program for psychiatric indications in the public insurance system. Any introduction of esketamine for psychiatric indications would require local sanitary registration and specific payer decisions by public or private insurers. # #

Ketamine is an accepted, legal medicinal anaesthetic and analgesic agent used in Dominican healthcare settings under conventional medical regulation (consistent with the WHO Model List of Essential Medicines which includes parenteral ketamine for anaesthesia). In practice, ketamine is available for approved medical uses (e.g., anesthesia in hospitals) and covered as part of usual hospital care where that hospital’s billing/insurance arrangements permit; however, there is no clear, documented national public reimbursement policy or structured program in the Dominican Republic that reimburses ketamine-based psychedelic or off-label psychiatric protocols (such as repeated subanaesthetic infusions for depression) as a standard insured benefit — such psychiatric uses would be off-label and, if used, would typically be arranged privately or within clinical research frameworks and subject to institutional review and local regulatory oversight. # #

Currently classified as a controlled substance under the national law and regulation; there is no authorised medical or reimbursed access to DMT-based therapies in routine care in the Dominican Republic, and access is limited to authorised scientific research if permitted. Components containing DMT are subject to control, which constrains legal ritual or therapeutic use outside of explicit regulatory exceptions. # #

Currently classified under the national drug-control framework as a controlled tryptamine with no authorised medical use or reimbursement outside approved clinical research. There is no public insurance coverage for 5‑MeO‑DMT therapies. # #

Currently classified as a controlled substance under the national framework with no authorised medical use or reimbursement for ibogaine-assisted treatment in routine care; access is limited to authorised research if specifically permitted by national regulators. # #

While plant-based brews such as ayahuasca are not ordinarily listed by common name in scheduling texts, the active component DMT is controlled under Dominican law; therefore, ayahuasca use is constrained by control of constituent controlled substances and there is no recognised, reimbursed medical pathway for ayahuasca-assisted therapy in the Dominican Republic outside authorised research or exceptional regulatory exemptions. # #

Mescaline is identified as a controlled substance under the national drug-control legal framework and is not available as a reimbursed medical treatment; routine medical use is not authorised outside approved clinical research or explicit regulatory exception. # #

Members of the 2C family (e.g., 2C‑B/2C‑I and related substituted phenethylamines) are controlled under broad national scheduling provisions and are not authorised for medical use or reimbursement in routine healthcare; access would be limited to tightly controlled research if permitted. Currently there is no public-payor reimbursement for any 2C‑family therapy. # #